Bibliography
- Dessain SK, Spears JL. Hodgkin disease. Available from: http://emedicine.medscape.com/article/201886-overview [Accessed 2nd February 2011]
- Josting A, Muller H, Borchmann P, Dose intensity of chemotherapy in patients with relapses Hodgkin's lymphoma. J Clin Oncol 2010;28:5074-80
- Younes A, Bartlett N, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphoma. N Engl J Med 2010;363:1812-21
- Josting A, Rudolph C, Mapara M, Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116-35
- Ansell SM, Horwitz SM, Engert A, Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-9
- Forero-Torres A, Leonard JP, Younes A, A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9
- Francisco JA, Cerveny GG, Meyer DL, cA10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
- Oflazoglu E, Kissler KM, Sievers EL, Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008;142:69-83
- An SGN-35 trial for patients who have previously participated in an SGN-35 study. Available from: http://clinicaltrials.gov/ct2/show/NCT00947856?term=brentuximab&rank=9 [Accessed 11th February 2011]
- A phase 3 study of brentuximab vedotin (SGN-35) in patients at high risk of residual Hodgkin lymphoma following stem cell transplant (the AETHERA trial). Available from: http://clinicaltrials.gov/ct2/show/NCT01100502?term=brentuximab&rank=4 [Accessed 11th February 2011]
- A phase 1 study of brentuximab vedotin combined with ABVD for Hodgkin lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01060904?term=brentuximab&rank=2 [Accessed 11th February 2011]
- Johnston PB, Inwards DJ, Colgan JP, A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Haematol 2010;85:320-4
- Dickinson M, Ritchie D, DeAngelo DJ, Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol 2009;147:97-101